Zimmer Biomet (NYSE:ZBH) Lowered to Hold Rating by Wall Street Zen

Wall Street Zen lowered shares of Zimmer Biomet (NYSE:ZBH) from a buy rating to a hold rating in a report published on Saturday morning.

A number of other analysts have also weighed in on the company. Barclays lowered their target price on Zimmer Biomet from $104.00 to $100.00 and set an “underweight” rating for the company in a research note on Thursday. Evercore upgraded shares of Zimmer Biomet from an “in-line” rating to an “outperform” rating and raised their price objective for the company from $94.00 to $120.00 in a research report on Monday, January 5th. Citigroup reiterated a “buy” rating on shares of Zimmer Biomet in a research report on Wednesday. Weiss Ratings reissued a “hold (c-)” rating on shares of Zimmer Biomet in a research note on Wednesday, January 21st. Finally, Sanford C. Bernstein boosted their price objective on shares of Zimmer Biomet from $97.00 to $99.00 and gave the stock a “market perform” rating in a research report on Friday, January 9th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $106.20.

Zimmer Biomet Stock Performance

NYSE ZBH opened at $96.32 on Friday. Zimmer Biomet has a 1-year low of $84.59 and a 1-year high of $114.44. The company has a 50 day moving average of $90.10 and a 200-day moving average of $95.64. The company has a current ratio of 1.98, a quick ratio of 1.39 and a debt-to-equity ratio of 0.55. The firm has a market cap of $19.09 billion, a price-to-earnings ratio of 27.21, a PEG ratio of 1.97 and a beta of 0.62.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 EPS for the quarter, topping analysts’ consensus estimates of $2.38 by $0.04. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The business had revenue of $2.24 billion for the quarter, compared to analyst estimates of $2.22 billion. During the same period in the prior year, the company earned $2.31 EPS. Zimmer Biomet’s revenue for the quarter was up 10.9% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. On average, equities analysts forecast that Zimmer Biomet will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, January 30th. Investors of record on Tuesday, December 30th were paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend was Tuesday, December 30th. Zimmer Biomet’s payout ratio is 27.12%.

Institutional Trading of Zimmer Biomet

A number of institutional investors have recently bought and sold shares of the business. Brighton Jones LLC acquired a new stake in shares of Zimmer Biomet during the fourth quarter worth $204,000. Sivia Capital Partners LLC bought a new position in Zimmer Biomet during the second quarter worth about $232,000. IFP Advisors Inc grew its position in shares of Zimmer Biomet by 8.3% during the 2nd quarter. IFP Advisors Inc now owns 1,947 shares of the medical equipment provider’s stock worth $178,000 after buying an additional 149 shares during the period. CWM LLC increased its stake in shares of Zimmer Biomet by 203.4% in the 2nd quarter. CWM LLC now owns 24,507 shares of the medical equipment provider’s stock valued at $2,235,000 after acquiring an additional 16,429 shares during the last quarter. Finally, MGO One Seven LLC raised its position in shares of Zimmer Biomet by 59.7% in the 2nd quarter. MGO One Seven LLC now owns 3,717 shares of the medical equipment provider’s stock valued at $339,000 after acquiring an additional 1,389 shares during the period. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.